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Anxiety disorders and inflammation in a large adult
cohort
N Vogelzangs1, ATF Beekman1, P de Jonge2 and BWJH Penninx1,2,3
Although anxiety disorders, like depression, are increasingly being associated with metabolic and cardiovascular burden, in
contrast with depression, the role of inflammation in anxiety has sparsely been examined. This large cohort study examines the
association between anxiety disorders and anxiety characteristics with several inflammatory markers. For this purpose, persons
(18–65 years) with a current (N¼ 1273) or remitted (N¼ 459) anxiety disorder (generalized anxiety disorder, social phobia, panic
disorder, agoraphobia) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and healthy
controls (N¼ 556) were selected from the Netherlands Study of Depression and Anxiety. In addition, severity, duration, age of
onset, anxiety subtype and co-morbid depression were assessed. Inflammatory markers included C-reactive protein (CRP),
interleukin (IL)-6 and tumor-necrosis factor (TNF)-a. Results show that after adjustment for sociodemographics, lifestyle and
disease, elevated levels of CRP were found in men, but not in women, with a current anxiety disorder compared with controls
(1.18 (s.e.¼ 1.05) versus 0.98 (s.e.¼ 1.07) mg l 1, P¼ 0.04, Cohen’s d¼ 0.18). No associations were found with IL-6 or TNF-a.
Among persons with a current anxiety disorder, those with social phobia, in particular women, had lower levels of CRP and IL-6,
whereas highest CRP levels were found in those with an older age of anxiety disorder onset. Especially in persons with an age of
onset after 50 years, CRP levels were increased compared with controls (1.95 (s.e.¼ 1.18) versus 1.27 (s.e.¼ 1.05) mg l 1,
P¼ 0.01, Cohen’s d¼ 0.37). In conclusion, elevated inflammation is present in men with current anxiety disorders. Immune
dysregulation is especially found in persons with a late-onset anxiety disorder, suggesting the existence of a specific late-onset
anxiety subtype with a distinct etiology, which could possibly benefit from alternative treatments.
Translational Psychiatry (2013) 3, e249; doi:10.1038/tp.2013.27; published online 23 April 2013
Introduction
Anxiety disorders are among themost prevalent and disabling
mental disorders.1,2 Increasing evidence links anxiety to
cardiovascular risk factors and diseases such as athero-
sclerosis,3 metabolic syndrome,4 and coronary heart dis-
ease.5,6 As low-grade systemic inflammation is clearly
involved in the etiology of these somatic conditions,7–9 it has
been hypothesized that inflammation has a role in anxiety
disorders and may form the link between anxiety disorders
and cardiovascular burden.10 Anxiety disorders are also
highly co-morbid with depression,11 which has recurrently
been associated with immune dysregulation.12,13 However,
unlike depression, very few studies have investigated the
relationship between anxiety disorders and inflammation. Two
recent studies have correlated anxiety symptoms with
increased cytokine levels, in particular C-reactive protein
(CRP).14,15 With regard to anxiety disorders, research has
mainly focused on posttraumatic stress disorder, in which high
levels of inflammatory markers have been found.16,17 Sparse
evidence from relatively small clinical studies (nE100)
suggests increased inflammatory activation in patients with
panic disorder18 and generalized anxiety disorder,19 which
seems to be independent of co-morbid depression.
As there is yet limited research on immune dysregulation
and anxiety, one can only speculate on the mechanisms
linking these two conditions. Experimentally induced stress
has been shown to produce an inflammatory reaction,20 which
has led researchers to suggest that it is in particular the
experience of acute stress, such as present in panic
disorders, causing the high levels of inflammation in anxiety.18
On the other hand, chronic stress may initiate changes in the
hypothalamic–pituitary–adrenal (HPA) axis and the immune
system, which in turn can trigger depression as well as
anxiety.21 These pathways are not independent as the HPA-
axis and the immune system are closely linked. Although the
HPA axis in normal situations should temper inflammatory
reactions, prolonged hyperactivity of the HPA axis could result
in blunted anti-inflammatory responses to glucocorticoids re-
sulting in increased inflammation.22,23 Likewise, it can be hypo-
thesized that immune changes associated with chronic disease
and aging,24 could induce similar anxiety-enhancing effects.
Although several mechanisms might explain an association
between inflammation and anxiety disorders, it can be expec-
ted that immune dysregulation is not a general phenomenon in
anxiety disorders, butmight be restricted to specific subgroups.
Whether this anxiety subgroup is defined by the type of
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disorder, the severity or duration of the disorder, the co-morbidity
with depression, or its age of onset, is yet to be examined.
The present study investigates the association between
several common anxiety disorders (generalized anxiety
disorder, social phobia, panic disorder, agoraphobia) and
heightened inflammation (CRP, interleukin (IL)-6, tumor
necrosis factor (TNF)-a) in a large sample of persons with
current and remitted anxiety disorders and healthy controls. In
addition, it will be examined whether specific anxiety
characteristics (severity, duration, age of onset, subtype,
depression co-morbidity) further discriminate those anxiety
patients with elevated inflammation.
Subjects and methods
Sample. The Netherlands Study of Depression and Anxiety
(NESDA) includes 2981 persons with and without depressive
and anxiety disorders, aged 18–65 years at the baseline
assessment in 2004–2007. Participants were recruited from
the community (19%), general practice (54%) and secondary
mental health care (27%) in order to reflect the broad range
and developmental trajectory of psychopathology. Persons
with insufficient command of the Dutch language or a primary
clinical diagnosis of bipolar disorder, obsessive compulsive
disorder, severe substance use disorder, psychotic disorder
or organic psychiatric disorder, as reported by themselves or
their mental health practitioner, were excluded. A detailed
description of the NESDA study design and sampling
procedures can be found elsewhere.25 The research protocol
was approved by the ethics committee of participating
universities and after complete description of the study all
respondents provided written informed consent.
During the baseline interview, the presence of anxiety
disorder (generalized anxiety disorder, social phobia, panic
disorder, agoraphobia) and depressive disorder (major
depressive disorder, dysthymia) was established using the
Composite Interview Diagnostic Instrument (CIDI) according
to Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition criteria.26 The CIDI is a highly reliable and valid
instrument for assessing depressive and anxiety disorders27
and was administered by specially trained research staff. In
addition, the severity of anxiety was measured in all
participants using the 21-item self-report Beck Anxiety
Inventory.28 For the present analyses, we selected persons
with a current (that is, past 6 months) or remitted (lifetime, but
not current) anxiety disorder and healthy controls. Healthy
controls had no lifetime anxiety or depressive disorder and a
Beck Anxiety Inventory score below 10, as a score of 10 or
above indicatesmild anxiety.29 Personswith anxiety disorders
were allowed to have a co-morbid depression. Of these 2342
persons, 54 were excluded due to missing information on
inflammatory markers, leaving a sample of 2288 persons for
the present study. Persons with missing data on inflammation
were less often female (55.6 versus 66.9%, P¼ 0.08), but did
not differ from included persons in terms of age, years of
education and the presence of anxiety disorder.
Anxiety characteristics. Next to subtype of CIDI anxiety
disorder diagnosis (generalized anxiety disorder, social
phobia, panic disorder, agoraphobia), anxiety characteristics
included anxiety symptoms severity as measured by the
Beck Anxiety Inventory, and anxiety symptoms duration,
using the Life Chart Interview (LCI).30 The LCI uses a
calendar method to determine life events during the past 4
years to refresh memory after which the presence of anxiety
and avoidance symptoms during that period is assessed.
From this, the per cent of time patients reported anxiety
symptoms was computed. The LCI has been used by other
large cohort studies31 and event history calendars such as
the LCI have been suggested a natural method of choice for
retrospective data collection.32 To be able to test whether
inflammation was in particular associated with anxiety
disorders with a later onset, as we had found for depres-
sion,33 age of anxiety onset was derived from the CIDI
interview. Last, the presence of a current co-morbid
depressive disorder (major depressive disorder, dysthymia)
was taken from the CIDI to check whether a possible
inflammation–anxiety association was independent of co-
morbid depression.
Inflammatory markers. Markers of inflammation were
assessed at the baseline NESDA measurement and included
CRP, IL-6 and TNF-a. Fasting blood samples of NESDA
participants were obtained in the morning between 0800 and
0900 hours and kept frozen at  80 1C. CRP and IL-6 were
assayed at the Clinical Chemistry Department of the VU
University Medical Center. High-sensitivity plasma levels of
CRP were measured in duplicate by an in-house ELISA
based on purified protein and polyclonal anti-CRP antibodies
(Dako, Glostrup, Denmark). Intra- and inter-assay coeffi-
cients of variation were 5% and 10%, respectively. Plasma
IL-6 levels were measured in duplicate by a high sensitivity
ELISA (PeliKine CompactTM ELISA, Sanquin, Amsterdam,
The Netherlands). Intra- and inter-assay coefficients of
variation were 8% and 12%, respectively. Plasma TNF-a
levels were assayed in duplicate at Good Biomarker Science,
Leiden, The Netherlands, using a high-sensitivity solid phase
ELISA (Quantikines HS Human TNF-a Immunoassay, R&D
systems, Minneapolis, MN, USA). Intra- and inter-assay
coefficients of variation were 10% and 15%, respectively.
Covariates. Sociodemographic characteristics included
sex, age and years of education. As lifestyle characteristics
can be associated with both anxiety and inflammation,
smoking status (never, former, current), alcohol intake (o1,
1–14 (women)/1–21 (men),414 (women)/421 (men) drinks
per week), physical activity (measured with the International
Physical Activity Questionnaire34 in MET-minutes (ratio of
energy expenditure during activity compared with rest times
the number of minutes performing the activity) per week) and
body mass index (weight in kilograms divided by height in
meters squared) were assessed. In addition, several
disease-related covariates were taken into account including
the presence of cardiovascular disease (assessed by self-
report supported by appropriate medication use (see
Vogelzangs et al.6 for detailed description)), the presence
of diabetes (fasting plasma glucose level X7.0mmol l 1 or
use of anti-diabetic medication (ATC code A10)) and the
number of other self-reported chronic diseases for which
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persons received treatment (including lung disease, osteoar-
thritis or rheumatic disease, cancer, ulcer, intestinal problem,
liver disease, epilepsy and thyroid gland disease). Medica-
tion use was assessed based on drug container inspection of
all drugs used in the past month and classified according to
the World Health Organization Anatomical Therapeutic
Chemical classification.35 Statin use (C10AA, C10B) and
use of systemic anti-inflammatory medication (M01A, M01B,
A07EB, A07EC) were assessed. Antidepressant medication
included regular use (450% of the time) of selective
serotonin reuptake inhibitors (SSRI; N06AB), serotonin-
norepinephrine reuptake inhibitors (SNRI; N06AX16,
N06AX21), tricyclic antidepressants (TCA; N06AA) and
tetracyclic antidepressants (TeCA; N06AX03, N06AX05,
N06AX11).
Statistical analyses. Baseline characteristics were com-
pared between men and women using w2 test for dichotomous
and categorical variables, independent samples t-test for
continuous variables, and Mann–Whitney U-test for inflam-
matory markers. For subsequent analyses, CRP, IL-6 and
TNF-a were ln-transformed to normalize distributions, but
back-transformed values are presented to enhance interpre-
tation. Associations between anxiety disorders and inflamma-
tory markers were examined using analyses of (co)variance,
and (adjusted) means across anxiety groups (no, remitted,
current) are presented. To take the effects of potential
confounding factors into account, three different models were
tested: unadjusted, adjusted for sociodemographics (sex, age,
education) and additionally adjusted for lifestyle and disease
(smoking status, alcohol intake, physical activity, body mass
index, cardiovascular disease, diabetes, number of other
chronic diseases, statins, anti-inflammatory medication). As
depression has been reported to differentially affect inflam-
mation in men and women,33 a sex-interaction for anxiety
disorders is plausible. Therefore, we tested sex-interactions
by including a sex anxiety disorder status interaction term.
When present, analyses were repeated sex stratified.
To test whether specific anxiety characteristics were related
to elevated inflammation levels, we performed linear regres-
sion analyses with inflammatory markers as the outcome for
each anxiety characteristic (severity, duration, age of onset,
subtype, depression co-morbidity) within the sample of
persons with a current anxiety disorder.
Results
Mean age of the study sample was 41.8 (s.d.¼ 13.1) years and
66.9%werewomen. Baseline characteristics of the total sample
and for men and women separately are shown in Table 1.
Women were younger, more often non-drinkers, had a lower
bodymass index, less often cardiovascular disease or diabetes
and less often used statins than men. In addition, women had
higher levels of CRP than men. All covariates were associated
with at least one of the inflammation markers, which has been
presented elsewhere.33 Pearson’s correlations between inflam-
matory markers were modest (CRP–IL-6: r¼ 0.31; CRP–TNF-
a: r¼ 0.13; IL-6–TNF-a: r¼ 0.12; all Po0.001).
Table 2 shows (adjusted) mean inflammation levels across
anxiety groups (controls, remitted, current) based on analyses
of (co)variance. In the total sample, higher CRP levels were
found in persons with a current anxiety disorder compared
with controls in unadjusted analyses (1.36 (s.e.¼ 1.04) versus
1.11 (s.e.¼ 1.05) mg l 1, P¼ 0.001), but after adjustment,
there were no associations between anxiety disorders and
any of the inflammation markers. However, a significant
sex anxiety disorder interaction was found for CRP
(remitted: P¼ 0.57; current: P¼ 0.002). Stratified analyses
for CRP showed that even after full adjustment for lifestyle and
disease, men with current anxiety disorders had higher levels
of CRP compared with controls (1.18 (s.e.¼ 1.05) versus 0.98
(s.e.¼ 1.07) mg l 1, P¼ 0.04, Cohen’s d¼ 0.18). In women,
anxiety disorders were not significantly associated with CRP.
No sex interactions were found for IL-6 (remitted: P¼ 0.47;
current: P¼ 0.40) or TNF-a (remitted: P¼ 0.92; current:
P¼ 0.87). As we have previously reported associations
between inflammatory levels and antidepressant use within
currently depressed persons,33 we checked the influence of
antidepressant use on our current results. Higher levels of
CRP were found in TCA/TeCA users within our present
sample of persons with current anxiety disorders (N¼ 1273;
P¼ 0.001). To examine whether the finding of elevated CRP
in currently anxious men was independent of TCA/TeCA use,
we excluded all men using TCA/TeCA (N¼ 36). Results
remained similar, although no longer significant (men with
current anxiety disorders versus controls: 1.13 (s.e.¼ 1.05)
versus 0.97 (s.e.¼ 1.07) mg l 1, P¼ 0.08, Cohen’s d¼ 0.15).
In addition, to reduce the possible confounding effects of
acute illness on inflammatory levels at the time of blood draw,
all persons who reported having had a cold or fever in the
week before blood drawwere excluded (N¼ 645), but findings
remained alike (men with current anxiety disorders versus
controls: 1.09 (s.e.¼ 1.06) versus 0.91 (s.e.¼ 1.07) mg l 1,
P¼ 0.06, Cohen’s d¼ 0.19).
To investigate whether specific anxiety characteristics
(severity, duration, age of onset, subtype, depression co-
morbidity) were associated with inflammation, linear regres-
sion analyses were performed within the subgroup of persons
with current anxiety disorders (N¼ 1273; Table 3). Anxiety
severity and duration did not correlate with inflammation.
Later age of anxiety disorder onset was associated with
elevated CRP levels (b¼ 0.053, P¼ 0.05), even after addi-
tional adjustment for TCA/TeCA use (b¼ 0.053, P¼ 0.05).
Persons with social phobia had lower levels of CRP
(b¼  0.053, P¼ 0.04) and IL-6 (b¼  0.052, P¼ 0.05)
compared with persons with other types of anxiety disorders.
The association between social phobia and IL-6 appeared to
be specific for women (b¼  0.089, P¼ 0.007), but not men
(b¼ 0.025, P¼ 0.61; P sex-interaction¼ 0.05). Co-morbid
depressive disorder did not further differentiate anxious
persons with elevated inflammation.
To further illustrate the findings with regard to age of onset,
we constructed five age of anxiety disorder onset groups
(o20, 20–30, 30–40, 40–50, X50). Figure 1 presents
adjusted means of back-transformed CRP levels across
controls and age of onset groups based on analysis of
covariance. CRP levels were only increased in persons with
an age of onset after 50 years (1.95 (s.e.¼ 1.18) versus 1.27
(s.e.¼ 1.05) mg l 1 in controls, P¼ 0.01, Cohen’s d¼ 0.37).
For comparison, adjusted mean CRP levels for persons with
Anxiety and inflammation
N Vogelzangs et al
3
Translational Psychiatry
cardiovascular disease were 1.62 (s.e¼ 1.11), illustrating the
clinical relevance of this finding. Excluding persons reporting
having had a cold or fever in the week before blood draw
(N¼ 513), yielded similar findings (age of onset after 50 years
versus controls: 1.73 (s.e.¼ 1.20) versus 1.18 (s.e.¼ 1.05)
mg l 1,P¼ 0.04, Cohen’s d¼ 0.35). Results were also similar
when the analysis of Figure 1 was restricted to the sample of
persons aged 50 years or above (N¼ 589; age of onset
after 50 years versus controls: 2.05 (s.e.¼ 1.16) versus 1.35
(s.e.¼ 1.08) mg l 1, P¼ 0.01, Cohen’s d¼ 0.40), underlining
that higher CRP in those with an age of onset of 50 years or
above was not due to the higher age itself in these persons.
Last, in a post-hoc analysis, we directly compared CRP levels
between persons with a late versus early onset of anxiety
disorder at a cutoff of 50 years, and found significantly higher
CRP levels in the late onset group (1.91 (s.e.¼ 1.19) versus
1.35 (s.e.¼ 1.03) mg l 1, P¼ 0.05, Cohen’s d¼ 0.30).
Discussion
The current study is one of the first and the largest to date to
examine the association between anxiety disorders and
inflammation. The results show that men with a current
anxiety disorder have somewhat increased levels of CRP,
even after taking a large set of lifestyle and disease factors
into account. Elevated levels of CRP were in particular found
in those persons with a late onset of the anxiety disorder.
Our results are in line with the few previous studies
examining the relationship between anxiety symptoms or
disorders with inflammation. Available evidence until now was
limited to assessing anxiety symptoms in the general
population,14,15 confined to specific anxiety disorders in small
clinical samples16–18 or in a heart disease population.19 Our
study adds to the literature by showing that elevated CRP
levels can be found among several common anxiety disorders
in a relatively large cohort of anxious persons and controls,
specifically in those with a later onset of the anxiety disorder.
CRP levels were in particular elevated among men with
anxiety disorders, which is in line with the large-scale study by
Liukkonen et al.,15 which showed an association between
anxiety symptoms and CRP only in men. In contrast, Pitsavos
et al.14 found associations between an anxiety symptoms
score and CRP levels in both men and women. Persons
included in the study by Pitsavos et al. were much older
Table 1 Baseline characteristics
Total sample (N¼ 2288) Men (N¼757) Women (N¼ 1531) P-valuesa
Sociodemographics
Age (years), mean (s.d.) 41.8 (13.1) 43.2 (13.1) 41.1 (13.0) 0.001
Education (years), mean (s.d.) 12.1 (3.3) 12.2 (3.3) 12.1 (3.2) 0.67
Lifestyle and disease
Smoking status 0.14
Never, % 28.3 25.6 29.6
Former, % 33.5 34.3 33.1
Current, % 38.2 40.0 37.4
Alcohol intake o0.001
o1 Drink a week, % 32.5 21.1 38.1
1–14 (women)/1–21 (men) drinks a week, % 56.3 67.5 50.8
414 (women)/421 (men) drinks a week, % 11.2 11.4 11.2
Physical activity (MET-minutes/week), mean (s.d.) 3644 (2999) 3711 (3304) 3611 (28361) 0.48
Body mass index, mean (s.d.) 25.6 (5.1) 26.1 (4.5) 25.3 (5.3) o0.001
Cardiovascular disease, % 6.2 10.0 4.2 o0.001
Diabetes, % 4.9 7.4 3.6 o0.001
Number of other chronic diseases, mean (s.d.) 0.4 (0.7) 0.4 (0.7) 0.4 (0.7) 0.14
Statin, % 6.4 9.5 4.9 o0.001
Anti-inflammatory medication, % 4.1 3.0 4.6 0.07
Anxiety characteristics
Anxiety disorder 0.001
Control, % 24.3 28.9 22.0
Remitted anxiety disorder, % 20.1 17.3 21.4
Current anxiety disorder, % 55.6 53.8 56.6
Within persons with a current anxiety disorder (N¼ 1273)
Severity (BAI score), mean (s.d.) 18.4 (10.9) 17.6 (10.7) 18.8 (10.9) 0.06
Duration (% of time), mean (s.d.) 56.6 (36.3) 58.7 (36.5) 55.6 (36.3) 0.17
Age of anxiety onset (years), mean (s.d.) 21.2 (12.8) 23.2 (13.9) 20.2 (12.1) o0.001
Generalized anxiety disorder, % 35.7 38.6 34.3 0.14
Social phobia, % 51.1 51.1 51.0 0.98
Panic disorder and/or agoraphobia, % 65.4 61.7 67.2 0.05
Co-morbid depressive disorder, % 58.4 57.2 59.0 0.55
Inflammatory markers
C-reactive protein (mg l 1), median (IQR) 1.20 (0.54–3.00) 1.01 (0.48–2.40) 1.33 (0.57–3.30) o0.001
Interleukin-6 (pgml 1), median (IQR) 0.75 (0.49–1.25) 0.77 (0.51–1.31) 0.75 (0.49–1.24) 0.25
Tumor necrosis factor-a (pgml 1), median (IQR) 0.80 (0.60–1.10) 0.80 (0.60–1.10) 0.70 (0.60–1.10) 0.13
Abbreviations: BAI, Beck anxiety inventory; IQR, interquartile range; s.d., standard deviation.
aBased on w2 test for dichotomous and categorical variables and independent samples t-test for continuous variables testing the difference betweenmen and women;
because of non-normal distributions, the Mann–Whitney U-test was used to test differences in raw inflammatory levels.
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(18–89 years; mean age 45 years) than those in the study by
Liukkonen et al. (all 31 years old), and slightly older than those
in the present study (18–65 years; mean age 42 years).
Perhaps sex differences become less clear with increasing
age, as a result of hormonal changes across the lifespan of
women, which affect inflammation levels.36 This could be in
line with our finding that CRP levels were elevated in bothmen
and women with a late onset of anxiety disorders.
Our findings with respect to anxiety disorders are also very
comparable to our earlier findings regarding depressive
disorders and inflammation.33 In that study, we found elevated
inflammation, specifically CRP, in depressed men, especially
among those with a later depression onset. The effect sizes
for CRP inmenwith a current disorder are also comparable for
anxiety (Cohen’s d¼ 0.18) and depressive (Cohen’s d¼ 0.21)
disorders. A trend for association with IL-6, which was found
for current depressive disorders in men, was not found for
current anxiety disorders. Of note is that in persons with an
anxiety disorder, a co-morbid depressive disorder was not
associated with higher inflammation levels, suggesting that
the effects found for anxiety disorders are independent of
depression.
In line with our previous findings for current depressive
disorders,33 CRP levels were in particular elevated among
Table 3 Associationa of anxiety characteristics with inflammatory marker levels in persons with current anxiety disorders (N¼ 1273)
Anxiety characteristic Nc CRPb IL-6b TNF-ab
b P b P b P
Severity of anxiety symptoms (BAI) 1254 0.027 0.31 0.017 0.54 0.017 0.57
Duration of anxiety symptoms 1208 0.026 0.34 0.001 0.99 0.004 0.88
Age of anxiety disorder onset 1254 0.053 0.05 0.019 0.53 0.044 0.15
Generalized anxiety disorder 1273 0.021 0.40 0.036 0.19 0.042 0.13
Social phobia 1273 0.053 0.04 0.052 0.05 0.013 0.64
Panic disorder and/or agoraphobia 1273 0.011 0.66 0.026 0.35 0.014 0.62
Co-morbid depressive disorder 1273 0.016 0.53 0.026 0.34 0.025 0.37
Abbreviations: BAI, Beck anxiety inventory; CRP, C-reactive protein; IL-6, interleukin-6; TNF-a, tumor necrosis factor-a.
aBased on linear regression analyses adjusted for sex, age, education, smoking status, alcohol intake, physical activity, body mass index, cardiovascular disease,
diabetes, number of other chronic diseases, statins and anti-inflammatorymedication. bCRP, IL-6 and TNF-awere ln-transformed to normalize distributions. cN differs
due to missing values on some of the anxiety characteristics.
Table 2 Adjusted mean inflammatory marker levels across anxiety groups
Controls Remitted anxiety disorder Current anxiety disorder
Mean (s.e.) P Mean (s.e.) P Mean (s.e.) P
CRP, mg l 1a
Total sample N¼ 556 N¼ 459 N¼ 1273
Unadjustedb 1.11 (1.05) Ref 1.25 (1.06) 0.14 1.36 (1.04) 0.001
Adjustedc 1.20 (1.05) Ref 1.24 (1.06) 0.66 1.33 (1.03) 0.10
Adjustedd 1.28 (1.05) Ref 1.21 (1.05) 0.46 1.30 (1.03) 0.74
Sex-interactione 0.57 0.002
Men N¼ 219 N¼ 131 N¼407
Unadjustedb 0.84 (1.08) Ref 1.02 (1.11) 0.15 1.25 (1.06) o0.001
Adjustedc 0.90 (1.08) Ref 0.98 (1.10) 0.50 1.22 (1.06) 0.002
Adjustedd 0.98 (1.07) Ref 0.96 (1.09) 0.82 1.18 (1.05) 0.04
Women N¼ 337 N¼ 328 N¼866
Unadjustedb 1.34 (1.07) Ref 1.35 (1.07) 0.89 1.42 (1.04) 0.46
Adjustedc 1.41 (1.07) Ref 1.40 (1.07) 0.95 1.37 (1.04) 0.74
Adjustedd 1.48 (1.06) Ref 1.36 (1.06) 0.35 1.36 (1.04) 0.26
IL-6, pgml1a
Total sample N¼ 556 N¼ 459 N¼ 1273
Unadjustedb 0.73 (1.04) Ref 0.71 (1.05) 0.78 0.79 (1.03) 0.08
Adjustedc 0.75 (1.04) Ref 0.70 (1.05) 0.30 0.78 (1.03) 0.35
Adjustedd 0.79 (1.04) Ref 0.70 (1.04) 0.06 0.77 (1.03) 0.63
Sex-interactione 0.47 0.40
TNF-a, pgml1a
Total sample N¼ 556 N¼ 459 N¼ 1273
Unadjustedb 0.82 (1.03) Ref 0.81 (1.03) 0.75 0.83 (1.02) 0.73
Adjustedc 0.84 (1.03) Ref 0.81 (1.03) 0.43 0.83 (1.02) 0.75
Adjustedd 0.85 (1.03) Ref 0.82 (1.03) 0.35 0.82 (1.02) 0.41
Sex-interactione 0.92 0.87
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6; TNF-a, tumor necrosis factor-a.
aTo normalize distributions CRP, IL-6 and TNF-a were ln-transformed; for interpretation purposes presented means are back-transformed. bBased on analyses of
variance. cBased on analyses of covariance adjusted for (sex,) age and education. dBased on analyses of covariance additionally adjusted for smoking status, alcohol
intake, physical activity, body mass index, cardiovascular disease, diabetes, number of other chronic diseases, statins and anti-inflammatory medication.
eSex-interactions are based on the fully adjusted model including anxiety status and a sexanxiety status interaction term.
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persons with a later onset of anxiety disorders. In contrast,
characteristics that are more often associated with an early
age of onset, such as higher severity and longer duration were
not associated with increased inflammation. Also, in our
sample, women had an earlier age of anxiety disorder onset
than men, possibly contributing to the lack of an overall
association between anxiety disorders and inflammation in
women. Furthermore, we found that CRP levels were lowest
among persons with social phobia when compared with other
anxiety disorders, in particular in women. Social phobia has
been reported to have a much earlier age of onset compared
with generalized anxiety disorder or panic disorder,37 which
was confirmed in our sample (16.6 versus 25.9 years,
Po0.001). To our knowledge, no other study has yet
examined the association between social phobia and inflam-
mation. In our study, only nine persons with social phobia had
an disorder onset at or after 50 years. Therefore, low
inflammation levels in persons with social phobia cannot
explain our findings for elevated CRP levels in persons with an
age of anxiety disorder onset after 50 years. A recent study by
Copeland et al.38 showed that, after taking health-related
behaviors into account, generalized anxiety disorder was not
associated with elevated CRP levels among children and
adolescents. These findings argue against the idea that the
inflammation–anxiety association is merely a result of acute
stress experienced in anxiety disorders. Although we cannot
make inferences about etiology based on our cross-sectional
analyses, our current findings are in line with the growing
evidence suggesting a distinct etiology involving vascular/
metabolic/inflammatory factors in depression or anxiety
disorders with an onset later in life.39–42 Possibly,
accumulating psychological and physical stress across the
life-span might induce immunological changes24 that even-
tually results in depression and anxiety.
In our previous report,33 we had found differences in
inflammation levels among different classes of antidepressant
medication use, which was confirmed for higher CRP in TCA/
TeCA users within our present sample of persons with current
anxiety disorders. Excluding persons using TCA or TeCA,
resulted in a slightly weaker effect size for the association
between current anxiety disorder and CRP in men. This might
suggest that the elevated CRP levels in men with current
anxiety disorders are for some part due to use of TCA/TeCA.
On the other hand, persons using TCA/TeCA might represent
the more severe cases of anxiety disorders, in which case
exclusion of these persons leads to an underestimation of the
association. Adjustment for TCA/TeCA use had no effect on
our findings for age of anxiety disorder onset, suggesting that
late-onset anxiety disorders are independently associated
with higher levels of CRP.
What are the clinical implications of our findings? First, our
finding of increased CRP levels in particularly those with a late
onset of the anxiety disorder might implicate the existence of a
specific late-onset anxiety subtype with a distinct etiology. As
we have found similar results for depression33 and because
depression and anxiety are highly co-morbid disorders,11 this
might suggest that depression and anxiety with a late onset
share a similar etiology and represent one particular group of
disorders, which might be more distinct from other depressive
or anxiety disorders, which present earlier in life. As we can
only speculate on etiology based on our cross-sectional
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Figure 1 Adjusted mean (s.e.) C-reactive protein (CRP) levels across controls and age of anxiety disorder onset groups. Based on analysis of covariance adjusted for sex,
age, education, smoking status, alcohol intake, physical activity, body mass index, cardiovascular disease, diabetes, number of other chronic diseases, statins and anti-
inflammatory medication; to normalize distributions, CRP was ln-transformed and for interpretation purposes presented means were back-transformed.
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existence of an etiologically distinct late-onset subtype.
Second, if confirmed, a distinct etiology for late-onset
disorders implicates different treatment strategies for this
subgroup. Perhaps anti-inflammatory medication or lifestyle
interventions, such as exercise, for which (some) evidence
exists that they normalize immune and metabolic dysregula-
tion,43 as well as improve depressive symptoms to some
degree,44,45 could be beneficial in persons with late onset
anxiety disorders as well.
Our study has some important strengths such as a large
sample size, assessment of multiple inflammatory markers,
clinical diagnoses of several anxiety disorders, adequate
adjustment for potential confounders and the ability to
examine the role of anxiety characteristics. However, some
limitations need to be acknowledged. As our data are cross-
sectional, we cannot make any inferences about the direction
of the association. Also, althoughwe adjusted for a large set of
possible confounding factors, unmeasured poor lifestyle
behaviors or health factorsmay be the explaining link between
inflammation and anxiety disorders. For instance, subclinical
cardiovascular disease could possibly precede both inflam-
mation and anxiety. On the other hand, subclinical disease
may be one pathway of how inflammation leads to anxiety in
later life. Longitudinal studies are needed to investigate
whether immune dysregulation is a precursor or the result of
anxiety, or whether this relationship is bidirectional. Further,
like most other studies, we assessed circulating levels of
inflammatory markers, which show a high degree of intra-
individual variation that could explain the rather modest
overall associations between anxiety disorders and inflam-
mation in our study.
In conclusion, our results show that low-grade systemic
inflammation is present inmenwith anxiety disorders. Elevated
inflammation is in particular found in bothmen and womenwith
the onset of anxiety disorder later in life. Longitudinal studies
are needed to confirm inflammation as an etiological factor in
anxiety disorders with a late-life onset, followed by intervention
trials investigating new treatment strategies (for example, anti-
inflammatory medication, lifestyle interventions) for this subset
of persons with late-onset anxiety.
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